Dr. Chambers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3838 N Campbell Ave
Tucson, AZ 85719Phone+1 520-694-8888Fax+1 520-694-0348
Education & Training
- Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 1984 - 1986
- Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 1980 - 1984
- The Warren Alpert Medical School of Brown UniversityClass of 1980
Certifications & Licensure
- AZ State Medical License 2004 - 2026
- CT State Medical License 1984 - 2004
- IL State Medical License 1983 - 1984
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Top Doctors:Arizona State Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Join now to see all
Clinical Trials
- Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer Start of enrollment: 2005 Jan 01
- Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer Start of enrollment: 2007 Sep 01
- Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Start of enrollment: 2009 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda
Scientific Reports. 2024-12-02 - 1 citationsTolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, John K Chan, Nicoline Raaschou-Jensen
European Journal of Cancer. 2024-09-01 - Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk.Xia Wang, Ho-Hyung Woo, Michele Wei, Steven Gibson, Mitzi Miranda
Medrxiv. 2024-02-29
Grant Support
- Regulation Of CSF-1 In Ovarian CancerNational Cancer Institute2004–2006
- Regulation Of CSF-1 In Ovarian CancerNational Cancer Institute2002–2003
- Regulation Of CSF 1 And Urokinase In Ovarian CancerNational Cancer Institute1995–1999
- Regulation Of C-FMS Proto-Oncogene In Epithelial CancersEunice Kennedy Shriver National Institute Of Child Health &Human Development1993–1995
- Contemporary Approaches To Ovarian CancerNational Cancer Institute1993
- CSF-1 And Drug Resistance In Reproductive CancersEunice Kennedy Shriver National Institute Of Child Health &Human Development1990–1991
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: